Severe Chronic PainMatrix LQNCT00699335
Matrifen® for Therapy of Severe Chronic Pain®
An observational study of Severe Chronic Pain, run by Nycomed at 1,235 sites in Germany.
Trial summary
The aim of the study was to evaluate the efficacy and safety of Matrifen® in patients with severe and chronic pain who could only be sufficiently treated with opioid analgetics (WHO class 3). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Severe Chronic Pain
- What is being tested?
- Fentanyl
- How many people
- 5,308 participants
- Where
- 1,235 sitesGermany
- Study dates
- Jun 2008to Jul 2009
- Phase
- Observational
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Outpatients
Main inclusion criteria:
- Outpatients with severe, chronic pain
Main exclusion criteria:
- Hypersensitivity to fentanyl
- Co-administration of monoamineoxidase-inhibitors
- Pregnancy
- Respiratory depression
- Chronic obstructive pulmonary disease (COPD)
- Drug abuse
- Impairment of CNS functions
- Other criteria as defined in the Summary of Product Characteristics (Chapter 4.3)
Trial locations and contacts
1,235 sites in 1 country.
300 sites in 1 country
Germany300 sites
Nycomed Deutschland GmbH
Aalen, 73430
Nycomed Deutschland GmbH
Abensberg, 93326
Nycomed Deutschland GmbH
Adelebsen, 37139
Nycomed Deutschland GmbH
Ahaus, 48683
Nycomed Deutschland GmbH
Ahlen, 59229
Nycomed Deutschland GmbH
Ahrensburg, 22926
Nycomed Deutschland GmbH
Albstadt, 72459
Nycomed Deutschland GmbH
Aldenhoven, 52457
Nycomed Deutschland GmbH
Alfeld, 31061
Nycomed Deutschland GmbH
Alfhausen, 49594
Nycomed Deutschland GmbH
Allersberg, 90584
Nycomed Deutschland GmbH
Alsfeld, 36304
Nycomed Deutschland GmbH
Altdorf, 84032
Nycomed Deutschland GmbH
Altenburg, 04600
Nycomed Deutschland GmbH
Altenstadt, 63674
Nycomed Deutschland GmbH
Althengstett, 75382
Nycomed Deutschland GmbH
Altlußheim, 68804
Nycomed Deutschland GmbH
Alzenau in Unterfranken, 63755
Nycomed Deutschland GmbH
Angermünde, 16278
Nycomed Deutschland GmbH
Annweiler am Trifels, 76855
Nycomed Deutschland GmbH
Ansbach, 91522
Nycomed Deutschland GmbH
Apolda, 99510
Nycomed Deutschland GmbH
Arnsberg, 59821
Nycomed Deutschland GmbH
Arnstadt, 99310
Nycomed Deutschland GmbH
Ascheberg, 24326
Nycomed Deutschland GmbH
Aschendorf, 26871
Nycomed Deutschland GmbH
Aschersleben, 06449
Nycomed Deutschland GmbH
Asslar-Werdorf, 35614
Nycomed Deutschland GmbH
Attendorn, 57439
Nycomed Deutschland GmbH
Attenkirchen, 85395
Nycomed Deutschland GmbH
Aue, 08280
Nycomed Deutschland GmbH
Auerbach, 08209
Nycomed Deutschland GmbH
Augsburg, 86150
Nycomed Deutschland GmbH
Augsburg, 86159
Nycomed Deutschland GmbH
Augsburg, 86161
Nycomed Deutschland GmbH
Augsburg, 86163
Nycomed Deutschland GmbH
Augsburg, 86167
Nycomed Deutschland GmbH
Augsburg, 86179
Nycomed Deutschland GmbH
Augustdorf, 32832
Nycomed Deutschland GmbH
Aumühle, 21521
Nycomed Deutschland GmbH
Babenhausen, 64832
Nycomed Deutschland GmbH
Backnang, 71522
Nycomed Deutschland GmbH
Bad Arolsen, 34454
Nycomed Deutschland GmbH
Bad Bederkesa, 27624
Nycomed Deutschland GmbH
Bad Berka, 99438
Nycomed Deutschland GmbH
Bad Bevensen, 29549
Nycomed Deutschland GmbH
Bad Bramstedt, 24576
Nycomed Deutschland GmbH
Bad Düben, 04849
Nycomed Deutschland GmbH
Bad Dürkheim, 67098
Nycomed Deutschland GmbH
Bad Dürrenberg, 06231
Nycomed Deutschland GmbH
Bad Dürrheim, 78073
Nycomed Deutschland GmbH
Bad Eilsen, 31707
Nycomed Deutschland GmbH
Bad Essen, 49152
Nycomed Deutschland GmbH
Bad Frankenhausen, 06567
Nycomed Deutschland GmbH
Bad Homburg, 61348
Nycomed Deutschland GmbH
Bad Klosterlausnitz, 07639
Nycomed Deutschland GmbH
Bad Kreuznach, 55543
Nycomed Deutschland GmbH
Bad Krozingen, 79189
Nycomed Deutschland GmbH
Bad Langensalza, 99947
Nycomed Deutschland GmbH
Bad Lausick, 04651
Nycomed Deutschland GmbH
Bad Lauterberg im Harz, 37431
Nycomed Deutschland GmbH
Bad Liebenwerda, 04924
Nycomed Deutschland GmbH
Bad Nauheim, 61231
Nycomed Deutschland GmbH
Bad Neuenahr-Ahrweiler, 53474
Nycomed Deutschland GmbH
Bad Oeynhausen, 32545
Nycomed Deutschland GmbH
Bad Oeynhausen, 32547
Nycomed Deutschland GmbH
Bad Oldesloe, 23843
Nycomed Deutschland GmbH
Bad Salzuflen, 32105
Nycomed Deutschland GmbH
Bad Salzuflen, 32108
Nycomed Deutschland GmbH
Bad Salzungen, 36433
Nycomed Deutschland GmbH
Bad Schandau, 01814
Nycomed Deutschland GmbH
Bad Schwalbach, 65307
Nycomed Deutschland GmbH
Bad Segeberg, 23795
Nycomed Deutschland GmbH
Bad Tennstedt, 99955
Nycomed Deutschland GmbH
Bad Tölz, 83646
Nycomed Deutschland GmbH
Bad Wilsnack, 19336
Nycomed Deutschland GmbH
Bad Windsheim, 91438
Nycomed Deutschland GmbH
Bad Wörishofen, 86825
Nycomed Deutschland GmbH
Badel, 39624
Nycomed Deutschland GmbH
Baden-Baden, 76532
Nycomed Deutschland GmbH
Baden-Baden, 76534
Nycomed Deutschland GmbH
Badenhausen, 37534
Nycomed Deutschland GmbH
Badersleben, 38836
Nycomed Deutschland GmbH
Bahrdorf, 38459
Nycomed Deutschland GmbH
Bakum, 49456
Nycomed Deutschland GmbH
Balingen, 72336
Nycomed Deutschland GmbH
Ballrechten-Dottingen, 79282
Nycomed Deutschland GmbH
Bamberg, 96047
Nycomed Deutschland GmbH
Bamberg, 96049
Nycomed Deutschland GmbH
Bamberg, 96052
Nycomed Deutschland GmbH
Bautzen, 02625
Nycomed Deutschland GmbH
Bayreuth, 95444
Nycomed Deutschland GmbH
Beckum, 59269
Nycomed Deutschland GmbH
Berching, 92334
Nycomed Deutschland GmbH
Bergfelde, 16562
Nycomed Deutschland GmbH
Bergisch Gladbach, 51429
Nycomed Deutschland GmbH
Bergisch Gladbach, 51465
Nycomed Deutschland GmbH
Bergisch Gladbach, 51469
Nycomed Deutschland GmbH
Bergkamen, 59192
Nycomed Deutschland GmbH
Bergrheinfeld, 97493
Nycomed Deutschland GmbH
Berlin, 10117
Nycomed Deutschland GmbH
Berlin, 10243
Nycomed Deutschland GmbH
Berlin, 10247
Nycomed Deutschland GmbH
Berlin, 10315
Nycomed Deutschland GmbH
Berlin, 10317
Nycomed Deutschland GmbH
Berlin, 10318
Nycomed Deutschland GmbH
Berlin, 10365
Nycomed Deutschland GmbH
Berlin, 10405
Nycomed Deutschland GmbH
Berlin, 10409
Nycomed Deutschland GmbH
Berlin, 10435
Nycomed Deutschland GmbH
Berlin, 10437
Nycomed Deutschland GmbH
Berlin, 10587
Nycomed Deutschland GmbH
Berlin, 10629
Nycomed Deutschland GmbH
Berlin, 10711
Nycomed Deutschland GmbH
Berlin, 10713
Nycomed Deutschland GmbH
Berlin, 10715
Nycomed Deutschland GmbH
Berlin, 10717
Nycomed Deutschland GmbH
Berlin, 10787
Nycomed Deutschland GmbH
Berlin, 10827
Nycomed Deutschland GmbH
Berlin, 10961
Nycomed Deutschland GmbH
Berlin, 10997
Nycomed Deutschland GmbH
Berlin, 12043
Nycomed Deutschland GmbH
Berlin, 12047
Nycomed Deutschland GmbH
Berlin, 12049
Nycomed Deutschland GmbH
Berlin, 12051
Nycomed Deutschland GmbH
Berlin, 12057
Nycomed Deutschland GmbH
Berlin, 12101
Nycomed Deutschland GmbH
Berlin, 12103
Nycomed Deutschland GmbH
Berlin, 12107
Nycomed Deutschland GmbH
Berlin, 12109
Nycomed Deutschland GmbH
Berlin, 12163
Nycomed Deutschland GmbH
Berlin, 12207
Nycomed Deutschland GmbH
Berlin, 12247
Nycomed Deutschland GmbH
Berlin, 12347
Nycomed Deutschland GmbH
Berlin, 12351
Nycomed Deutschland GmbH
Berlin, 12439
Nycomed Deutschland GmbH
Berlin, 12459
Nycomed Deutschland GmbH
Berlin, 12559
Nycomed Deutschland GmbH
Berlin, 12587
Nycomed Deutschland GmbH
Berlin, 12623
Nycomed Deutschland GmbH
Berlin, 12627
Nycomed Deutschland GmbH
Berlin, 12683
Nycomed Deutschland GmbH
Berlin, 12687
Nycomed Deutschland GmbH
Berlin, 13055
Nycomed Deutschland GmbH
Berlin, 13125
Nycomed Deutschland GmbH
Berlin, 13127
Nycomed Deutschland GmbH
Berlin, 13187
Nycomed Deutschland GmbH
Berlin, 13353
Nycomed Deutschland GmbH
Berlin, 13357
Nycomed Deutschland GmbH
Berlin, 13409
Nycomed Deutschland GmbH
Berlin, 13467
Nycomed Deutschland GmbH
Berlin, 13509
Nycomed Deutschland GmbH
Berlin, 13581
Nycomed Deutschland GmbH
Berlin, 13597
Nycomed Deutschland GmbH
Berlin, 14163
Nycomed Deutschland GmbH
Berlin, 14169
Nycomed Deutschland GmbH
Berlin, 14193
Nycomed Deutschland GmbH
Berlin, 14195
Nycomed Deutschland GmbH
Berlin, 14199
Nycomed Deutschland GmbH
Bernau, 16321
Nycomed Deutschland GmbH
Bernburg, 06406
Nycomed Deutschland GmbH
Berne, 27804
Nycomed Deutschland GmbH
Bernsbach, 08315
Nycomed Deutschland GmbH
Beselich, 65614
Nycomed Deutschland GmbH
Beucha, 04824
Nycomed Deutschland GmbH
Beverungen, 37688
Nycomed Deutschland GmbH
Biberach, 88400
Nycomed Deutschland GmbH
Bielefeld, 33602
Nycomed Deutschland GmbH
Bielefeld, 33739
Nycomed Deutschland GmbH
Bietigheim-Bissingen, 74321
Nycomed Deutschland GmbH
Bilzingsleben, 06578
Nycomed Deutschland GmbH
Bingen, 55411
Nycomed Deutschland GmbH
Bingen, 72511
Nycomed Deutschland GmbH
Bisingen, 72406
Nycomed Deutschland GmbH
Bitterfeld-Wolfen, 06749
Nycomed Deutschland GmbH
Blankenfelde-Mahlow, 15831
Nycomed Deutschland GmbH
Blankenhain, 99444
Nycomed Deutschland GmbH
Blieskastel, 66440
Nycomed Deutschland GmbH
Böblingen, 71032
Nycomed Deutschland GmbH
Bobritzsch, 09627
Nycomed Deutschland GmbH
Bocholt, 46395
Nycomed Deutschland GmbH
Bochum, 44787
Nycomed Deutschland GmbH
Bochum, 44789
Nycomed Deutschland GmbH
Bochum, 44791
Nycomed Deutschland GmbH
Bochum, 44805
Nycomed Deutschland GmbH
Bochum, 44807
Nycomed Deutschland GmbH
Bodenwerder, 37619
Nycomed Deutschland GmbH
Böhlen, 04564
Nycomed Deutschland GmbH
Bonndorf, 79848
Nycomed Deutschland GmbH
Borna, 04552
Nycomed Deutschland GmbH
Bottrop, 46240
Nycomed Deutschland GmbH
Boxberg, 02943
Nycomed Deutschland GmbH
Brake, 26919
Nycomed Deutschland GmbH
Brakel, 33034
Nycomed Deutschland GmbH
Bramsche, 49565
Nycomed Deutschland GmbH
Brand-Erbisdorf, 09618
Nycomed Deutschland GmbH
Braunsbedra, 06242
Nycomed Deutschland GmbH
Braunschweig, 38112
Nycomed Deutschland GmbH
Braunschweig, 38114
Nycomed Deutschland GmbH
Braunschweig, 38124
Nycomed Deutschland GmbH
Bredstedt, 25821
Nycomed Deutschland GmbH
Breidenbach, 35236
Nycomed Deutschland GmbH
Breitenbrunn, 08359
Nycomed Deutschland GmbH
Bremen, 28209
Nycomed Deutschland GmbH
Bremen, 28327
Nycomed Deutschland GmbH
Bremen, 28359
Nycomed Deutschland GmbH
Bremen, 28717
Nycomed Deutschland GmbH
Bremen, 28759
Nycomed Deutschland GmbH
Bremen, 28779
Nycomed Deutschland GmbH
Bremerhaven, 27568
Nycomed Deutschland GmbH
Bremerhaven, 27570
Nycomed Deutschland GmbH
Bremerhaven, 27578
Nycomed Deutschland GmbH
Bremerhaven, 27580
Nycomed Deutschland GmbH
Bremervörde, 27432
Nycomed Deutschland GmbH
Brilon, 59929
Nycomed Deutschland GmbH
Bruchsal, 76646
Nycomed Deutschland GmbH
Bruck, 92436
Nycomed Deutschland GmbH
Brüel, 19412
Nycomed Deutschland GmbH
Büchen, 21514
Nycomed Deutschland GmbH
Büchenbach, 91186
Nycomed Deutschland GmbH
Bückeburg, 31675
Nycomed Deutschland GmbH
Bühl-Altschweier, 77815
Nycomed Deutschland GmbH
Bühlertann, 74424
Nycomed Deutschland GmbH
Burg, 39288
Nycomed Deutschland GmbH
Burgbrohl, 56659
Nycomed Deutschland GmbH
Burgdorf, Hanover, 31303
Nycomed Deutschland GmbH
Burgstädt, 09217
Nycomed Deutschland GmbH
Burkardroth, 97705
Nycomed Deutschland GmbH
Burkhardtsdorf, 09235
Nycomed Deutschland GmbH
Burscheid, 51399
Nycomed Deutschland GmbH
Castrop-Rauxel, 44575
Nycomed Deutschland GmbH
Castrop-Rauxel, 44577
Nycomed Deutschland GmbH
Celle, 29221
Nycomed Deutschland GmbH
Celle, 29223
Nycomed Deutschland GmbH
Chemnitz, 09116
Nycomed Deutschland GmbH
Chemnitz, 09119
Nycomed Deutschland GmbH
Chemnitz, 09126
Nycomed Deutschland GmbH
Chemnitz, 09127
Nycomed Deutschland GmbH
Chemnitz, 09130
Nycomed Deutschland GmbH
Chemnitz, 09224
Nycomed Deutschland GmbH
Claußnitz, 09236
Nycomed Deutschland GmbH
Clausthal-Zellerfeld, 38678
Nycomed Deutschland GmbH
Clenze, 29459
Nycomed Deutschland GmbH
Cloppenburg, 49661
Nycomed Deutschland GmbH
Coburg, 96450
Nycomed Deutschland GmbH
Cochem, 56812
Nycomed Deutschland GmbH
Coesfeld, 48653
Nycomed Deutschland GmbH
Cölbe, 35091
Nycomed Deutschland GmbH
Cologne, 50679
Nycomed Deutschland GmbH
Cologne, 50769
Nycomed Deutschland GmbH
Cologne, 50823
Nycomed Deutschland GmbH
Cologne, 50825
Nycomed Deutschland GmbH
Cologne, 50827
Nycomed Deutschland GmbH
Cologne, 50937
Nycomed Deutschland GmbH
Cologne, 50996
Nycomed Deutschland GmbH
Cologne, 50997
Nycomed Deutschland GmbH
Cologne, 50999
Nycomed Deutschland GmbH
Cologne, 51063
Nycomed Deutschland GmbH
Cologne, 51065
Nycomed Deutschland GmbH
Cologne, 51069
Nycomed Deutschland GmbH
Cologne, 51103
Nycomed Deutschland GmbH
Coswig, 01640
Nycomed Deutschland GmbH
Coswig, 06869
Nycomed Deutschland GmbH
Cottbus, 03050
Nycomed Deutschland GmbH
Crawinkel, 99330
Nycomed Deutschland GmbH
Crimmitschau, 08451
Nycomed Deutschland GmbH
Crivitz, 19089
Nycomed Deutschland GmbH
Crostwitz, 01920
Nycomed Deutschland GmbH
Cuxhaven, 27478
Nycomed Deutschland GmbH
Cuxhaven-Altenwalde, 27478
Nycomed Deutschland GmbH
Dachau, 85221
Nycomed Deutschland GmbH
Dahlwitz-Hoppegarten, 15366
Nycomed Deutschland GmbH
Darmstadt, 64293
Nycomed Deutschland GmbH
Dassel, 37586
Nycomed Deutschland GmbH
Dautphetal, 35232
Nycomed Deutschland GmbH
Deggendorf, 94469
Nycomed Deutschland GmbH
Deggingen, 73326
Nycomed Deutschland GmbH
Delitzsch, 04509
Nycomed Deutschland GmbH
Denzlingen, 79211
Nycomed Deutschland GmbH
Dessau, 06844
Nycomed Deutschland GmbH
Dessau, 06847
Nycomed Deutschland GmbH
Detmold, 32756
Nycomed Deutschland GmbH
Dettenheim, 76706
Nycomed Deutschland GmbH
Dettmannsdorf-Kölzow, 18334
Nycomed Deutschland GmbH
Diedorf, 99988
Nycomed Deutschland GmbH
Diepholz, 49356
Nycomed Deutschland GmbH
Dillingen, 66763
Nycomed Deutschland GmbH
Dillingen-Diefflen, 66763
Nycomed Deutschland GmbH
Dinkelsbühl, 91550
Nycomed Deutschland GmbH
Döbeln, 04720
Nycomed Deutschland GmbH
Dogern, 79804
Nycomed Deutschland GmbH
Dörentrup, 32694
Nycomed Deutschland GmbH
Dörpen, 26892
Nycomed Deutschland GmbH
Dorsten, 46282
Nycomed Deutschland GmbH
Dortmund, 44135
Nycomed Deutschland GmbH
Dortmund, 44137
Nycomed Deutschland GmbH
Dortmund, 44139
Nycomed Deutschland GmbH
Dortmund, 44143
Nycomed Deutschland GmbH
Dortmund, 44269
Nycomed Deutschland GmbH
Dortmund, 44287
About this study
Official title: Efficacy of Matrifen® in Patients Older Than 18 Years With Severe, Chronic Pain Including Quality of Life Questionnaire
The aim of the study was to evaluate the efficacy and safety of Matrifen® in patients with severe and chronic pain who could only be sufficiently treated with opioid analgetics (WHO class 3).
- Conditions
- Severe Chronic Pain
- Being tested
- Fentanyl
- Keywords
- pain, fentanyl, transdermal patch
- Medical subject headings
- Chronic Pain, Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FentanylDrug
Fentanyl transdermal patch. This was an observational study - therefore, the physician decided about dosage according to individual needs
What is being measured
The primary outcome is the main question the study is designed to answer.
Patient's Assessment of Pain Severity Score
Assessment on a Visual Analogue Scale from 0=No pain to 10=Most severe pain
Measured: Before and after therapy with Matrifen® (4 weeks)
Physician's Final Assessment of the Efficacy of Therapy With Matrifen®
Assessment on a scale: Excellent, good, satisfactory, dissatisfactory
Measured: After 4 week therapy with Matrifen®
EQ-5D (Optional): Domain Mobility
This outcome measure to assess patients quality of life is based on an optional standardised patient questionnaire (EQ-5D).
Questions on a scale from 1-3 at initial and final visit:
- I have no problems in walking around
- I have some problems in walking around
- I am confined to bed
Measured: Before and after therapy with Matrifen® (4 weeks)
EQ-5D (Optional): Domain Self Care
This outcome measure to assess patients quality of life is based on an optional standardised patient questionnaire (EQ-5D).
Questions on a scale from 1-3 at initial and final visit:
- I have no problems with self-care
- I have some problems washing or dressing myself
- I am unable to wash or dress myself
Measured: Before and after therapy with Matrifen® (4 weeks)
EQ-5D (Optional): Domain Usual Activities
This outcome measure to assess patients quality of life is based on an optional standardised patient questionnaire (EQ-5D).
Questions on a scale from 1-3 at initial and final visit:
- I have no problems with performing my usual activities
- I have some problems with performing my usual activities
- I am unable to perform my usual activities
Measured: Before and after therapy with Matrifen® (4 weeks)
EQ-5D (Optional): Pain / Discomfort
This outcome measure to assess patients quality of life is based on an optional standardised patient questionnaire (EQ-5D).
Questions on a scale from 1-3 at initial and final visit:
- I have no pain or discomfort
- I have moderate pain or discomfort
- I have extreme pain or discomfort
Measured: Before and after therapy with Matrifen® (4 weeks)
EQ-5D (Optional): Domain Anxiety / Depression
This outcome measure to assess patients quality of life is based on an optional standardised patient questionnaire (EQ-5D).
Questions on a scale from 1-3 at initial and final visit:
- I am not anxious or depressed
- I am moderately anxious or depressed
- I am extremely anxious or depressed
Measured: Before and after therapy with Matrifen® (4 weeks)
EQ-5D (Optional): European Index Score
Index derived from the five EQ-5D-items (= mobility, self care, usual activities, pain/discomfort, anxiety/depression) resulting in a value from -1= very ill to 1=full health
Measured: Before and after therapy with Matrifen® (4 weeks)
EQ-5D (Optional): Visual Analogue Scale
Visual Analogue Scale (VAS) from 0 =worst imaginable health status, 100 =best imaginable health status
Measured: Before and after therapy with Matrifen® (4 weeks)
Secondary outcomes (4)
Physician's Assessment of the Skin Tolerability of the Fentanyl-patches
Assessment on a scale: Excellent, good, satisfactory, dissatisfactory
Measured: After 4 week therapy with Matrifen®
Patient's Assessment of the Acceptance of the Fentanyl-patches
Assessment on a scale: Excellent, good, satisfactory, dissatisfactory
Measured: After 4 week therapy with Matrifen®
Physician's Assessment of the Adhesion Properties of the Fentanyl-patches
Assessment on a scale: Excellent, good, satisfactory, dissatisfactory
Measured: After 4 week therapy with Matrifen®
Physician's Final Assessment of the Tolerability of Matrifen®
Assessment on a scale: Excellent, good, satisfactory, dissatisfactory
Measured: After 4 week therapy with Matrifen®
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jun 2008 (estimated)
- Study startJun 2008
- Primary completionJul 2009
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Severe Chronic PainStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 5,308 participants (actual)
Sponsor and investigators
- Lead sponsor
- Nycomed
- Sponsor type
- Industry (pharma, biotech, devices)
- Investigators
- Dr. Thomas D. Bethke, MD, MBA, Study director, Nycomed Deutschland GmbH, 78467 Konstanz, Germany
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00699335
- Sponsor's protocol ID
- Matrix LQ, FT-1300-028
- Acronym
- Matrix LQ
- Status last verified
- May 2012
- First submitted
- 17 Jun 2008
- Last updated
- 8 May 2012
- Results posted
- Yes, on ClinicalTrials.gov
Study at a glance
From the registry record, last updated by the sponsor on 8 May 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy of Matrifen® in Patients Older Than 18 Years With Severe, Chronic Pain Including Quality of Life Questionnaire
- ClinicalTrials.gov ID
- NCT00699335
- Acronym / sponsor ID
- Matrix LQ / Matrix LQ, FT-1300-028
- Conditions
- Severe Chronic Pain
- Keywords
- pain, fentanyl, transdermal patch
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 5,308 participants (actual)
- Lead sponsor
- NycomedIndustry (pharma, biotech, devices)
- Study start
- Jun 2008
- Primary completion
- Jul 2009 (actual)
- First posted
- 18 Jun 2008 (estimated)
- Results
- Posted 12 Aug 2010
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the study was to evaluate the efficacy and safety of Matrifen® in patients with severe and chronic pain who could only be sufficiently treated with opioid analgetics (WHO class 3).
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Outpatients
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| FentanylFentanyl transdermal patch. This was an observational study - therefore, the physician decided about dosage according to individual needs | Drug | – |
Primary outcome
Patient's Assessment of Pain Severity Score
Time frame: Before and after therapy with Matrifen® (4 weeks)
Assessment on a Visual Analogue Scale from 0=No pain to 10=Most severe pain
Physician's Final Assessment of the Efficacy of Therapy With Matrifen®
Time frame: After 4 week therapy with Matrifen®
Assessment on a scale: Excellent, good, satisfactory, dissatisfactory
EQ-5D (Optional): Domain Mobility
Time frame: Before and after therapy with Matrifen® (4 weeks)
This outcome measure to assess patients quality of life is based on an optional standardised patient questionnaire (EQ-5D). Questions on a scale from 1-3 at initial and final visit: 1. I have no problems in walking around 2. I have some problems in walking around 3. I am confined to bed
EQ-5D (Optional): Domain Self Care
Time frame: Before and after therapy with Matrifen® (4 weeks)
This outcome measure to assess patients quality of life is based on an optional standardised patient questionnaire (EQ-5D). Questions on a scale from 1-3 at initial and final visit: 1. I have no problems with self-care 2. I have some problems washing or dressing myself 3. I am unable to wash or dress myself
EQ-5D (Optional): Domain Usual Activities
Time frame: Before and after therapy with Matrifen® (4 weeks)
This outcome measure to assess patients quality of life is based on an optional standardised patient questionnaire (EQ-5D). Questions on a scale from 1-3 at initial and final visit: 1. I have no problems with performing my usual activities 2. I have some problems with performing my usual activities 3. I am unable to perform my usual activities
EQ-5D (Optional): Pain / Discomfort
Time frame: Before and after therapy with Matrifen® (4 weeks)
This outcome measure to assess patients quality of life is based on an optional standardised patient questionnaire (EQ-5D). Questions on a scale from 1-3 at initial and final visit: 1. I have no pain or discomfort 2. I have moderate pain or discomfort 3. I have extreme pain or discomfort
EQ-5D (Optional): Domain Anxiety / Depression
Time frame: Before and after therapy with Matrifen® (4 weeks)
This outcome measure to assess patients quality of life is based on an optional standardised patient questionnaire (EQ-5D). Questions on a scale from 1-3 at initial and final visit: 1. I am not anxious or depressed 2. I am moderately anxious or depressed 3. I am extremely anxious or depressed
EQ-5D (Optional): European Index Score
Time frame: Before and after therapy with Matrifen® (4 weeks)
Index derived from the five EQ-5D-items (= mobility, self care, usual activities, pain/discomfort, anxiety/depression) resulting in a value from -1= very ill to 1=full health
EQ-5D (Optional): Visual Analogue Scale
Time frame: Before and after therapy with Matrifen® (4 weeks)
Visual Analogue Scale (VAS) from 0 =worst imaginable health status, 100 =best imaginable health status
4 secondary outcomes
Physician's Assessment of the Skin Tolerability of the Fentanyl-patches
Time frame: After 4 week therapy with Matrifen®
Patient's Assessment of the Acceptance of the Fentanyl-patches
Time frame: After 4 week therapy with Matrifen®
Physician's Assessment of the Adhesion Properties of the Fentanyl-patches
Time frame: After 4 week therapy with Matrifen®
Physician's Final Assessment of the Tolerability of Matrifen®
Time frame: After 4 week therapy with Matrifen®
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 May 2012.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Severe Chronic Pain
Not yet recruiting
Empowered Relief for Severe Pain After Cesarean Delivery During the Inpatient Period
Severe Pain, Cesarean Section Complications
RecruitingObservational study
Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation
Opioid-induced Constipation
Active, not recruiting
Effects of Virtual Walking on Chronic Pain and Psychological Distress for Individuals With Severe Mobility Impairment
Severe Mobility Impairment, Spinal Cord Injuries (SCI)
Active, not recruiting
Enhanced Recovery After Major Surgery and Chronic Pain for Total Knee Arthroplasty
Chronic Pain, Opioid Use
RecruitingPhase 2
MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress Disorder
Post Traumatic Stress Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Dr. Thomas D. Bethke, MD, MBA study director
Nycomed Deutschland GmbH, 78467 Konstanz, Germany
1,235 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Severe Chronic Pain, run by Nycomed at 1,235 sites in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 May 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1,235 sites in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 12 Aug 2010). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Patient's Assessment of Pain Severity Score (time frame: Before and after therapy with Matrifen® (4 weeks)). The study lists 9 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 May 2012.